Madrigal pharmaceuticals announces rolling submission of new drug application to u.s. fda seeking accelerated approval of resmetirom for the treatment of nash with liver fibrosis

Conshohocken, pa., june 30, 2023 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), initiated a rolling submission of a new drug application (nda) to the u.s. food and drug administration (fda) seeking accelerated approval of resmetirom for the treatment of nash with liver fibrosis. madrigal has submitted the majority of the nda to the fda and plans to submit the remaining components in july 2023. the company will request a priority review of the nda.
MDGL Ratings Summary
MDGL Quant Ranking